
Description: In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to a new report from biopharma market research publisher, Spectra Intelligence.

“The chemotherapy market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade” says expert report author Dr Sarah Crawford PhD, Associate Professor of Biology and Director of Experimental Chemotherapy at Southern Connecticut State University, USA.

With more than 25 million people affected by cancer globally, and an estimated 5 million people dying each year as a result of cancer, new treatments are clearly needed to curtail these high mortality statistics despite the availability of effective cancer drugs such as Herceptin and Avastin. Dr Crawford cautions however that although there are very exciting and promising novel cancer therapeutics on the horizon with limitless potential, enthusiasm must be tempered by the need to identify those chemotherapy approaches that may have the greatest potential for therapeutic success and suggests that there is a need to distinguish important new entries to the cancer therapeutics market from those therapy approaches that may not fare as well on the world market.

Biopharmaceutical industry analyst Tim Atkinson, who reviewed the report, said “Dr Crawford has provided an exceptionally comprehensive first-rate analysis of our current understanding of cancer biology, cancer treatment approaches, diagnosis and management, and hopes for the future given the complexity and heterogeneity of this devastating disease. The report uniquely highlights the deficiencies and possibilities of cancer research and cancer drug development, which will undoubtedly help to create significant market opportunities and change the landscape for cancer treatments in the future.”

Dr Crawford adds “The world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcomes. Immunotherapies, monoclonal antibodies, new reformulations, and multimodal chemotherapy treatment regimens that combined with an ever-evolving understanding of the intricacies of cancer and the identification of new potential cell targets, will be the some of the new weapons in our fight against cancer”.

This new report from Spectra Intelligence, Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities, provides an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, R&D programs, and innovating companies and products. The reader will benefit from authoritative critical review, market forecasts to 2016, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate research and industrial growth, and create new market opportunities.

Objectives of the Report
The objectives of this report are to provide an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, pipeline programs, and innovating companies and products. It is hoped that the reader will benefit from critical review, market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Research Methodology
The contents of this report are derived from the author’s own research and analysis and other source material, which may comprise the following:
- Company information
- Personal communication
WHAT CAN I LEARN FROM THIS REPORT?
- Market potential for each of the novel cancer therapeutics in late stage clinical development
- Which new cancer therapeutics are likely to produce the best clinical results
- Which areas of preclinical drug research are likely to produce successful chemotherapies over the next few years
- The potential global market for newly approved cancer drugs
- The impact of new drugs on the global cancer market
- Which cancer drugs which have received recent US FDA approval
- Which pipeline cancer drugs which are most likely to receive US FDA approval in the near future
- The global market for specific types of cancer drugs
- The most successful biopharmaceutical companies currently engaged in chemotherapy product development
- Anticipated revenues for newly launched cancer drugs
- Sales forecasts for approved chemotherapies to 2016
- The current status of cancer chemotherapy in general and with regard to specific types of cancer
- The major issues involved in the research and development of chemotherapies
- Which types of cancer therapeutics are currently in research and development

REPORT HIGHLIGHTS AND KEY FINDINGS
- The current market for chemotherapies is estimated at US$42 billion and is forecast to increase approximately 17% to US$49 billion by 2012
- Critical assessment of the challenges to the development of better, more efficacious cancer treatments with fewer side effects
- Analysis of the problems associated with the use of traditional cancer therapeutics, eg. drug resistance, lack of clinical efficacy, side effects
- Focused analysis of the global prevalence of cancer: incidence, mortality and survival rates as they relate to new directions in cancer research
- Identification of the major classes of cancer drugs currently in research and development using the newest technologies and genetic approaches
- Highlights the most successful cancer therapeutics that may serve as prototypes for the research and development of more effective drugs
- Market analysis of trends in the cancer biotech industry to 2016
- Concise product review data for the most innovative and productive biopharmaceutical companies
- Assessment of all recent clinical trial data for investigational cancer drugs and prospects for approval by regulatory agencies
- Comparative assessment of new drugs with similar therapeutic targets
- Assessment of the newest clinical approaches to the treatment of cancer

Products Mentioned
- Gardasil (Merck)
- Cervarix (GlaxoSmithKline)
- Sutent – Pfizer
- Sorafenib (BAY43-9006) - Bayer/Onyx
- Panitumumab - Amgen/Abgenix
- Tykerb (Lapatinib)
- Eltrombopag
- Casopitant
- Femara
- PTKZK
- Introgen Therapeutics: Advexin
- United Therapeutics: OvaRex
- GPC Biotech AG: Satraplatin
- Cell Therapeutics: Xyotax
- NeoPharm: LEP-ETU
- Genta Pharmaceuticals: Genasense
- SuperGen: Orathecin 2
- Dendreon: Provenge
- Bayer: Sorafenib
- Iboctadekin
- Vestipitant
- Ispenesib
- Pazopanib
- Relacatib
- Elacridar
- RAD001
- Patupilone
- PKC412
- ST1571
- Gimatecan
- AMN107
- AEE788
- INGN225
- INGN241
- INGN401
- Xinlay (Atrasentan)

Contents:

- Contents List
- List of Tables
- List of Figures
- List of Abbreviations
- Executive Summary
- Objective of the Report
- Research Methodology

Chapter 1. Introduction to Cancer: Epidemiology, Pathophysiology, Diagnosis, and Treatment

Cancer Epidemiology
Global Epidemiology of Cancer
Global Statistics (World Health Organization - WHO)
Cancer Incidence and Mortality by Geographical Regions Worldwide
Cancer Epidemiology, United Kingdom (Office of National Statistics)
Cancer Incidence and Mortality
United Kingdom: Current Incidence Trends
Incidence by Age Group, United Kingdom
Current Mortality Trends in the United Kingdom
Survival Trends for Most Common Cancers in the United Kingdom
Current Cancer Statistics in the United States - American Cancer Society and Surveillance, Epidemiology and End Results Program (SEER)
Current Incidence and Mortality Rates for the Most Common Cancers in the United States
Current Cancer Estimates in the United States, 2005
Incidence and Mortality Rates by Racial Group, United States
Aetiology, Pathophysiology, and Diagnosis of Cancer by Type: Europe, United Kingdom and United States
Lung Cancer
Aetiology of Lung Cancer
Risk Factors for Lung Cancer
Pathophysiology of Lung Cancer
Diagnosis of Lung Cancer
Treatment of Lung Cancer
Lung Cancer: Outcome
Colorectal Cancer
Aetiology and Pathophysiology
Risk Factors for Colon Cancer
Diagnosis of Colon Cancer
Treatment of Colon Cancer
Leukaemias
Hodgkin's Disease
Non-Hodgkin's Lymphoma
Chemotherapy Drugs Approved by the United States Food and Drug Administration
Chemotherapy Side Effects
Clinical Treatment Administration Protocols
Chemotherapy Drugs and Market Opportunities
Chemotherapy Drug Reformulation
Novel Drug Delivery Systems

Chapter 4. The Market for Cancer Chemotherapies
The Market for Chemotherapies
The Global Cancer Market: Trends, Estimates, Economics, and Outlook
Cancer Market: Overview
Best-Selling Oncology Products
Pharmaceutical Product Growth in Oncology
Licensing and Chemotherapy Products
Cancer Treatments and Pharmacoeconomics
Critical Factors Affecting the High Pricing of Patented Cancer Drugs
Generic Erosion
High Costs of the New Super Drugs
Healthcare Costs: United States
Prescription Drug Costs and Coverage
Healthcare Reimbursement Issues: United States
Local Community Health Services
Private Sector Health Programs: Managed Care
Healthcare Purchasing Cooperatives: Federal Employers Health Benefits Program
Uninsured Americans
Current Issues in United States Healthcare Policy
Healthcare Policies: United Kingdom
National Health Service/National Institute for Health and Clinical Excellence
Healthcare Policies: United States versus United Kingdom
Healthcare Costs: Europe
Future Trends in the Cancer Market Based on Cancer Incidence
General Assessment of Future Trends in Cancer Therapeutics
Cancer Incidence, Survival and Mortality Rates: General Trends
Future Trends Based on Successful Treatment Approaches
General Considerations
Market Outlook for New Cancer Drugs
Current Chemotherapies: Product Review and Commercial Outlook
Genentech/Roche: Newly Approved Cancer Drug
Avastin
Tarceva
Rituxan
Herceptin
Genentech Bio-Oncology Market Data: 2004-2005
Roche
American Pharmaceutical Partners: Abraxane
MGI Pharma/Guildford Pharmaceuticals: Aloxi/Gliadel Wafer
Sanofi-Aventis: Taxotere/Eloxatin
Pfizer
Aromasin
Other Drugs in Pfizer's Portfolio
AstraZeneca
Arimidex
Faslodex
Zoladex
Iressa
Novartis
Gleevec
Zometa
Sandostatin
Femara
Chapter 5. Chemotherapies in Research and Development

General Trends in Global Oncology Markets Considered to Impact Chemotherapies in Research and Development

Important Therapeutic Areas Targeted for Research and Development

Promising New Oncology Drugs Poised for Market Entry

Therapeutic Clinical Oncology Candidates: Product Review

Cancer Vaccines: Gardasil (Merck) and Cervarix (GlaxoSmithKline)

Sutent – Pfizer

Sorafenib (BAY43-9006) - Bayer/Onyx

Panitumamab - Amgen/Abgenix

Prospective Oncology Drugs in Research and Development: Challenges for Drug Development

Promising Cancer Drugs in Late-Stage Clinical Trials

GlaxoSmithKline (GSK): Pipeline Products in Late-Stage Development

Tykerb (Lapatinib)

Eltrombopag

Casopitant

Novartis

Femara

PTKZK

Introgen Therapeutics: Advexin

United Therapeutics: OvaRex

GPC Biotech AG: Satraplatin

Cell Therapeutics: Xyotax

NeoPharm: LEP-ETU

Genta Pharmaceuticals: Genasense

SuperGen: Orathecin 2

Dendreon: Provenge

Bayer: Sorafenib

Promising Oncology Portfolios in Clinical Development

GlaxoSmithKline

Iboctadexkin

Vestipitant

Ispenesib

Pazopanib

Relacatib

Elacridar

Novartis

RAD001

Patupilone

PKC412

ST1571

Gimatecan

AMN107

AEE788

INGN225
Promising Biopharmaceutical Oncology Products in Clinical Development
Market Outlook for New Oncology Products in Late-Stage Development

Chapter 6: Cancer Research - Evaluating Drug Development and Market Opportunities
Current Themes and Trends in Cancer Research
Cancer Therapeutic Approaches in Research and Development
Supportive Therapies
Stem Cell Therapy
Immunotherapy
Emerging Biotechnologies
Recombinant Vaccines
Antisense Technology
Humanized Monoclonal Antibodies
Gene Therapy
Nanoparticle Technology
Current Biotechnological Cancer Therapeutic Approaches
Therapeutic Cellular Vaccines
Antigen/Adjuvant Vaccines
Whole Tumour Vaccines
Viral Vectors and DNA Vaccines
Idiotype Vaccines
Dendritophages
Molecular Targets of Therapeutic Vaccines
Therapeutic Vaccines in Clinical Trials
Passive Immunotherapy: Monoclonal Antibodies
Therapeutic Classes of Monoclonal Antibodies
Anti-CD20 Monoclonal Antibodies
Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies
Cell Death Targets
Small Molecule Targeted Anticancer Agents
Promising Small Molecule Therapeutic Targets in Research and Development
Tyrosine Kinase Inhibitors
Heterodimerization Inhibitors
STAT-3 Inhibitors
Cyclin-Dependent Kinase Inhibitors
Apoptosis Inducers
Hypoxia Inducible Factor-1 Pathway
Dipeptidyl Peptidase Inhibitors
Small Molecule Therapies for Cancer Cachexia
Small Molecule Immunostimulatory Agents
Small Molecule Adhesion Targets
Small Molecule Inhibitors: Resistance Mechanisms
New Chemical Entities - Standard Chemotherapy Approaches
New Investigative and Experimental Oncology Products
Novel Oncology Products: Nontargeted Experimental and Investigational Agents
Novel Drug Delivery Approaches in Research and Development
Novel Molecular Tumour Targets in Research and Development
Antisense Therapeutics
Novel Treatment Approaches in Early Preclinical Stages of Development
General Experimental Approaches
Chemopreventive Approaches
Development Outlook for Investigative/Experimental Oncology Products
General Considerations
Comparison of Therapeutic Treatment Modalities
Standard Chemotherapy
Small Molecule Inhibitors
Monoclonal Antibodies
Therapeutic Vaccines
Novel Treatment Delivery Approaches
Antisense Technologies

Chapter 7. Companies Developing Cancer Drugs
Leading Companies and Oncology Pipelines
Leading Multinational Companies and Oncology Products
Roche/Genentech
Novartis
Sanofi-Aventis
AstraZeneca
Eli Lilly
GlaxoSmithKline
Pfizer
Bristol-Myers Squibb
Schering-Plough
Johnson & Johnson
Other Oncology Focused Multinationals with Promising Pipelines
Abbott Laboratories/TAP Pharmaceutical
Merck & Co.
Takeda
Wyeth
Leading Biopharmaceutical Companies and Oncology Therapeutics
Amgen
Genentech
Genzyme
Serono
Medimmune
Chiron
Millennium Pharmaceuticals
Specialty Oncology Drug Discovery and Development Companies
Antigenics
Antisoma
Celgene
Cell Therapeutics
Ecopia Pharmaceutical Company
Helix BioPharma
ImClone Systems
Immunogen
Immusol
Inovio
Kosan Biosciences
MediGene
Milagen
MorphoSys
Myriad Pharmaceuticals
NeoRx
Protherics
Receptor Biologix
Regeneron Pharmaceuticals
Starpharma
Syrrx
U3 Pharma
Vertex Pharmaceuticals
Viventia Biotech
Xoma
Zymo Genetics
Other Discovery and Development Companies Specializing in Oncology Therapeutics
Reference Sources
List of Tables
Table 1.1 Highest Mortality Rates for Common Cancers
Table 1.2 Common Cancers in the United Kingdom Relative to Gender, 2004
Table 1.3 Incidence Trends for the Common Cancers in the United Kingdom (1990-2001)
Table 1.4 Mortality Rates in the United Kingdom, 2003
Table 1.5 Changes in 5- and 10-Year Survival Rates for Common Cancers, United Kingdom (1971-1999 Diagnosis)
Table 1.6 Incidence Rates for Common Cancers in the United States and United Kingdom
Table 1.7 Incidence and Mortality for Most Prevalent Cancer in the United States, 2005 Estimates for Men and Women
Table 1.8 Trends in Cancer Incidence, 2005 (% Total New Cases)
Table 1.9 Incidence, Mortality, Survival Trends, and Risk Factors for 10 Less Common Cancers in the United States
Table 1.10 Chemotherapy Options for Common Solid Tumour Malignancies by Disease Stage
Table 2.1 Viruses Implicated in Human Cancers
Table 2.2 Genes Most Commonly Identified in Human Cancers
Table 2.3 Genes Most Commonly Implicated in Major Human Cancers
Table 2.4 Chemotherapy Drugs Most Commonly Used to Treat Cancer
Table 2.5 General Staging Criteria Relevant to Chemotherapy Treatment Options in Solid Tumour Malignancies
Table 2.6 Chemotherapy Drugs Most Commonly Used to Treat Lung Cancer
Table 2.7 Most Common Treatment Options for Limited Small Cell Lung Carcinoma
Table 2.8 Most Common Treatment Options for Extensive Small Cell Lung Carcinoma
Table 2.9 Less Common Treatment Protocols for Extensive Small Cell Lung Carcinoma
Table 2.10 Experimental Chemotherapy for Advanced Lung Cancer
Table 2.11 Chemotherapy Drugs Most Commonly Used to Treat Colorectal Cancer
Table 2.12 Breast Cancer Chemotherapy Treatment Options
Table 2.13 Hormonal Therapies Used in the Treatment of Advanced Prostate Cancer
Table 2.14 Chemotherapy Drugs Most Commonly Used to Treat Ovarian Cancer
Table 2.15 Second-Line Treatments for Ovarian Cancer
Table 2.16 First-Line Combined Treatment Options for Advanced Ovarian Cancer
Table 2.17 Second-Line Combined Treatment Options for Resistant Ovarian Cancer
Table 2.18 Combined Chemotherapy Treatment Protocols for Acute Myeloid Leukaemia
Table 2.19 Common Drugs Used to Treat Chronic Myeloid Leukaemia
Table 2.20 Standard Treatment Options for Chronic Lymphocytic Leukaemia
Table 2.21 Standard Treatment Options for Hodgkin's Disease
Table 2.22 Treatment Options for Advanced Low-Grade Non-Hodgkin's Lymphoma
Table 2.23 Treatment Options for Early-Stage Fast-Growing Non-Hodgkin's Lymphoma
Table 2.24 Chemotherapy Drugs Approved by the United States Food and Drug Administration
Table 2.25 Drugs Administered to Combat Dose-Limiting Side Effects of Chemotherapy
Table 2.26 Estimated Global Sales (US$) and Forecasts of Leading Cancer Chemo-therapies, 2005-2016
Table 2.27 Approximate 2004 Expenditures for Chemotherapy Treatment of the Most Common Cancers Based on Incidence Rates
Table 2.28 Comparative Assessment of Positive Outcomes and Problems in Healthcare Systems, United States/United Kingdom
Table 2.29 Accessibility Ratings to New Cancer Drugs in Europe by Country
Table 2.30 Global Incidence and Mortality Ratios for the Most Common Cancers by Gender
Table 2.31 Global Incidence of Cancer by Site, Males and Females
Table 2.32 Estimated Percentage of Cancer Cases by Type in Men and Women, United States, 2005
Table 2.33 Predicted Average Lifetime Risk for Developing Cancer in Men and Women, 1999-2001 Estimates
Table 2.34 Five-Year Relative Survival Rates for the Most Common Cancers, United States, 1995-2000
Table 2.35 Comparison of 5-Year Survival Rates (%) for Most Common Cancers Over Three Time Periods, United States
Table 2.36 Death Rates from the Most Common Cancers in Men and Women, United States, 2005 Estimates
Table 2.37 New Anticancer Drugs with Strong Commercial Outlook Based on Clinical Efficacy
Table 2.38 New Drug Application Submissions (Oncology), United States Food and Drug Administration, 2005
Table 2.39 Comparison of Angiogenesis Inhibitors
Table 2.40 Major Projected Competitors: Oncology Drugs for Advanced Colon Cancer that Target Growth Factor Signal Pathways
Table 2.41 Tykerb: Summary of Clinical Trial Studies
Table 2.42 Late-Stage Oncology Products in Clinical Development Grouped by Mechanism of Action
Table 5.6 GlaxoSmithKline's Portfolio of Oncology Products in Research and Development
Table 5.7 Histone Deacetylase Inhibitors in Clinical Trials, 2006
Table 5.8 Biotechnological Oncology Products in Clinical Development by Clinical Phase
Table 5.9 Top Prospects for Market Success in the Oncology Pipeline
Table 6.1 United States Federal Drug Administration Approved and Investigational Monoclonal Antibody Therapeutics for Cancer
Table 6.2 Small Molecule Cancer Therapeutics in Research and Development by Clinical Phase
Table 6.3 Novel Druggable Tumour Targets in Research and Development
Table 6.4 Antisense Therapeutics in Research and Development
Table 7.1 The Top 50 Global Pharmaceutical Companies (2004 and 2005 Revenues)
Table 7.2 Global Portfolio Revenues and Market Share of Cancer Chemotherapies, 2005 (US$m)
Table 7.3 Roche’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.4 Novartis’ Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.5 Sanofi-Aventis’ Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.6 AstraZeneca’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.7 Eli Lilly's Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.8 GlaxoSmithKline’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.9 Pfizer’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.10 Bristol-Myers Squibb’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.11 Schering-Plough’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.12 Johnson & Johnson’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.13 Amgen’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.14 Genentech’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
Table 7.15 Additional Discovery and Development Companies Specializing in Oncology Therapeutics

List of Figures
Figure 1.1 Total Cancer Mortality (Age Standardized Rates)
Figure 1.2 Total Cancer Incidence (Age Standardized Rates)
Figure 1.3 Averaged Incidence of the Most Common Cancers in the United Kingdom for Men and Women
Figure 1.4 Incidence and Mortality of the 10 Most Common Cancers in the United States, 2005 Estimates
Figure 1.5 Lung Cancer Incidence (Age Standardized Rates)
Figure 1.6 Colon Cancer Incidence (Age Standardized Rates)
Figure 1.7 Breast Cancer Incidence/Mortality (Age Standardized Rates)
Figure 1.8 Prostate Cancer Incidence/Mortality (Age Standardized Rates)
Figure 1.9 Bladder Cancer Incidence (Age Standardized Rates)
Figure 1.10 Stomach Cancer Incidence (Age Standardized Rates)
Figure 1.11 Cervical Cancer Incidence/Mortality (Age Standardized Rates)
Figure 1.12 Melanoma Incidence (Age Standardized Rates)
Figure 1.13 Larynx Cancer Incidence (Age Standardized Rates)
Figure 1.14 Hodgkin's Disease Incidence (Age Standardized Rates)
Figure 1.15 Non-Hodgkin's Lymphoma Incidence (Age Standardized Rates)
Figure 1.16 Ovarian Cancer Incidence/Mortality (Age Standardized Rates)
Figure 1.17 Chemotherapy Regimens Used to Treat Non-Hodgkin's Lymphoma
Figure 2.1 Origins of Chemotherapy Resistance
Figure 2.2 Pharmacological Parameters of Drug Resistance
Figure 2.3 Proliferative Cell Cycle: Genes and Drug Targets
Figure 3.1 Factors Associated with Successful Chemotherapy Outcome
Figure 4.1 Best-Selling Chemotherapies, 2005 (US$m)
Figure 4.2 Market Share of the Top 10 Cancer Chemotherapies, 2005 & 2010
Figure 4.3 Growth Rates of Best-Selling Cancer Chemotherapy Drugs, 2005
Figure 4.4 Total Healthcare Costs: % Gross Domestic Product (GDP) by Country (2002)
Figure 4.5 Key Parameters of Cancer Drug Market
Figure 5.1 Therapeutic Classes of Oncology Drugs in the Product Pipeline
Figure 6.1 General Clinical Research Areas in Cancer Therapeutics
Figure 6.2 General Categories Of Therapeutic Enhancement Approaches
Figure 6.3 Biotechnology Approaches to Cancer Therapeutic Research and Development
Figure 6.4 Types of Therapeutic Cancer Vaccines in Clinical Research and Development
Figure 6.5 Tumour Antigen Targets Used in the Development of Therapeutic Cancer Vaccines
Figure 6.6 Monoclonal Antibody Therapeutic Targets
Figure 6.7 Small Molecule Therapy Targets
Figure 6.8 Combined Chemotherapy Treatment Possibilities
Figure 6.9 Cell Targets of Experimental Cancer Therapeutics: Drugs and Delivery Mode
Figure 7.1 Leading Oncology Companies by Chemotherapy Portfolio Revenues, 2005 (US$m)
Ordering: 

Order Online - http://www.researchandmarkets.com/reports/335548/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/335548/
Office Code: SCD2LPOH

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>3236</td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td>5091</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>7637</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World